For Help or to Order
+44 800 808 5251
Call Now!

Many people wonder: “What exactly is science doing to improve upon pre-existing hair loss therapies? Is any progress being made?”
The answer (thankfully) is “yes.”

Fortunately for hair loss sufferers, science is moving forward at a rapid pace. There are many companies working towards providing better solutions for customers living with Androgenetic Alopecia – each one pursuing several unique and intriguing research paths. Although it is unclear when any of these new treatments will ultimately reach the market, it is still exciting to watch each significant development unfold.

The main contenders in the race to bring more effective hair loss treatments to the masses are Histogen, Follica, Trichoscience, Aderans and Oxford BioLabs (the company behind TRX2). Although the exact mechanisms behind each one of these treatments are proprietary and quite complex, we have decided to provide brief overviews of the research conducted to date.

Histogen is currently conducting Phase I/II clinical studies for its injectable Hair Stimulating Complex (HSC). The Wnt Proteins contained in HSC have been proven to elicit new hair growth in individuals with Androgenetic Alopecia. Although Histogen is currently facing a lawsuit from one if its primary competitors, SkinMedica, the company plans to carry out further studies in Singapore starting February 2011. Due to relaxed Asian regulatory policies, the earliest projected date for commercialization is 2013.

Follica gained significant media attention in May of 2007 when its lead researcher, Dr. George Cotsarelis, published a paper that proved wound healing could induce to follicular neogenesis in adult mammals (a feat presumed to be impossible). In 2008 the company stated that a small proof of concept study was underway, but no results were released. Follica has since been silent, but their recent appearance at the 2010 Bio-Windhover Partnering Conference seems to indicate that they are moving toward clinical trials. Follica has added several prominent members to its team, including chairman Kirk Raab (former Genentech CEO) and CEO William Ju (formerly COO of PTC Therapeutics and Vice President of Pharmacia Corporation).

TrichoScience gained notoriety in 2009 when announced plans to begin a Phase I clinical trial in Europe. The company revealed that they had been conducting research since 2000, keeping quiet until they were more confident in their technology. The TrichoScience technique involves multiplying dermal sheath cup cells in culture and injecting them into recipient areas affected by pattern hair loss. TrichoScience has thus far given no date for commercialization, but Phase 1 is expected to begin during late 2010.

Aderans is currently conducting a Phase II clinical study in several major metropolitan areas across the United States. In February of 2010 the company announced that they would increase the breadth and scope of this phase by adding several new treatment centers and enlisting dozens of extra trialists. The Aderans approach is quite complex, multiplying several different types of cells in culture and introducing them into the skin with extra-cellular matrix bioscaffolds. It is unclear exactly when this treatment will hit the market (or how effective it will be), but a recent presentation given to Aderans shareholders projected a release date of 2014. During this presentation it was also revealed that Aderans possessed an entire portfolio of unique hair regeneration products.

Oxford BioLabs, the company behind TRX2, is pursuing a platform technology distinct from any other research approach to date. Our science is based on the recent discovery that potassium ion channels exist within human hair follicles. By targeting these small pore-forming structures, TRX2 products aim to restore full vitality and function of miniaturized hair follicles. In pursuit of this goal, we have announced the launch of our first product, TRX2® Molecular Supplement Capsules, and finalized clinical trial plans in several key areas. Our team is made up of world-class scientists and innovators who are all driven to persevere in formulating the most comprehensive treatment for men and women experiencing hair loss. The first updates (and products) will be released during 2010.

In the meantime we will keep you updated about where we are in the clinical process and we will continue to post news and articles regarding other available hair loss treatments.

See who's talking about TRX2®

* These statements have not been evaluated by any medical regulatory agencies. These products are not drugs or medicine, and are not intended to diagnose, treat, cure or prevent any disease. The TRX2® products are patent-pending food supplements and patent-pending cosmetic products that help users to maintain normal, healthy hair. Zinc, selenium and biotin contribute to the maintenance of normal hair. Normal hair is also characterised by healthy hair growth and non-excessive hair loss. Results may vary and are subject to your individual metabolism. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product. For risks and side-effects, please see the product package insert or info leaflet and consult your physician or healthcare specialist. Read full disclaimer. Read Legal Notices.

Disclaimer: The entire contents of this website are based upon the opinions and research of Oxford Biolabs Ltd., unless otherwise noted. Individual articles are based upon the opinions of the respective author, who may retain copyright as marked. Statements related to the rejuvenation, activation and stimulation of potassium channels are not intended to promote any specific ingredient, regimen, or use and should not be construed as evidence of the safety, effectiveness, or intended uses of the TRX2® products. It is purely presented as information about Oxford Biolabs's research focus and rationality behind formulating the TRX2® food supplement and cosmetics. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Oxford Biolabs Ltd. and its community. Oxford Biolabs Ltd. encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. See our terms of service and privacy policy and full disclaimer here

© 2009 - 2017 Oxford Biolabs Ltd. Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA, United Kingdom